ArticleBMJ public health2024
Evaluation of pre-exposure vaccine effectiveness against mpox during the 2022-2023 mpox outbreak in the Madrid region (Spain): a test-negative design.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pre-exposure vaccination in the high-risk population is crucial in controlling mpox resurgence in Canada.BMC infectious diseases · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: An appropriate vaccination approach is critical to control the current outbreak of mpox but there is little research providing information on its effectiveness, particularly under circumstances of limited vaccine availability. Methods: Pre-exposure vaccination campaign in the Madrid region, with the modified vaccinia Ankara-Bavarian Nordic was indicated in the risk groups from 18 July 2022.To evaluate the vaccine effectiveness (VE) of a dose of third-generation smallpox vaccine against mpox in the context of pre-exposure prophylaxis, a population-based indirect cohort study (Broome method) also known as test-negative design (TND) was conducted in the Madrid region (6 751 251 inhabitants). Logistic regression was used to obtain the adjusted VE in the TND with its time-response relationship and for the sensitivity analysis the conditional logistic regression for matched case-control groups. Results: By epidemiological surveillance, 1690 suspected episodes of mpox were detected of which 799 were cases and 891 controls.The overall adjusted effectiveness of the pre-exposure vaccination against mpox considering an induction period of 14 days, was 86.4% (95% CI 62.2% to 95.1%). VE increases, with a statistically significant time-response effect, being greater than 77.4% with a 95% confidence level from week 7. The VE at eighth week of vaccination was 99% (95% CI 81.7% to 99.9%). Conclusions: The effectiveness of single-dose pre-exposure vaccination against mpox seems very high. Therefore, it appears as a reliable measure to minimise the spread of mpox.The progressive increase in the effectiveness could justify the delay in the administration of the second dose in situations of shortage of vaccines or prioritisation in the vaccination of the maximum number of subjects at risk.Further studies evaluating the long-term effectiveness of the full vaccination would be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.